X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.
Lead Product(s): LineaDNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
Under the terms of this collaboration, Rottapharm Biotech will provide Takis with operational support, and with the financial resources needed to complete Phase I/II clinical trials.
Lead Product(s): COVID-eVax
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Rottapharm Biotech
Deal Size: Undisclosed Upfront Cash: $3.3 million
Deal Type: Collaboration June 04, 2020
Details:
Researchers at National Institute of Infectious Diseases found that Takis vaccines after a single vaccination developed antibodies in mice that can block the infection of SARS-CoV-2 on human cells.
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
The vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA.
Lead Product(s): Linear DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.
Lead Product(s): Linear DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2020
Details:
LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).
Lead Product(s): Linear DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Applied DNA Sciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
